U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
CAMBRIDGE, Mass., Nov. 09, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Stifel 2017 Healthcare Conference at 8:00 a.m. ET on Tuesday, November 14, 2017 in New York.
A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Investor Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]
Media Contact:
Katie Engleman
Pure Communications, Inc.
(910) 509-3977
[email protected]
